Domperidone
| Code | Size | Price |
|---|
| CDX-D0809-M100 | 100 mg | £102.00 |
Quantity:
| CDX-D0809-M500 | 500 mg | £377.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: n/a
Antibody Clone: n/a
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
R33812; 4-(5-Chloro-2-oxo-1-benzimidazolinyl)-1-[3-(2-oxobenzimidazolinyl)propyl]piperidine; Motilium; NSC 299589
Appearance:
White powder.
CAS:
57808-66-9
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS08
Handling Advice:
Protect from light and moisture.
Hazards:
H361
InChi:
InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)
InChiKey:
FGXWKSZFVQUSTL-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 57808-66-9. Formula: C22H24ClN5O2. MW: 425.91. Domperidone is a peripheral dopamine D2-like receptor antagonist that does not readily cross the blood-brain barrier. It demonstrates a potent affinity for the rat D2 receptor and is also reported to inhibit the rat D3 receptor. The antidopaminergic effects are cross-realted to its gastroprokinetic and antiemetic properties.
MDL:
MFCD00069256
Molecular Formula:
C22H24ClN5O2
Molecular Weight:
425.91
Package Type:
Vial
Precautions:
P280
Product Description:
Domperidone is a peripheral dopamine D2-like receptor antagonist that does not readily cross the blood-brain barrier. It demonstrates a potent affinity for the rat D2 receptor and is also reported to inhibit the rat D3 receptor. The antidopaminergic effects are cross-realted to its gastroprokinetic and antiemetic properties.
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
ClC1=CC(NC2=O)=C(C=C1)N2C(CC3)CCN3CCCN(C4=CC=CC=C4N5)C5=O
Solubility Chemicals:
Soluble in DMSO (10mg/ml).
Source / Host:
Synthetic.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
References
(1) D.B. Wilson & J.W. Dundee; Anaesthesia 34, 765 (1979) | (2) C.J. Niemegeers, et al.; Arch. Int. Pharmacodyn. Ther. 244, 130 (1980) | (3) M.C. Champion, et al.; Can. Med. Assoc. J. 135, 457 (1986) | (4) C. Lin, et al.; J. Pharmacol. Exper. Therap. 242, 950 (1987) | (5) P. Sokoloff, et al.; Nature 137, 146 (1990) | (6) A. Prakash & A.J. Wagstaff; Drugs 56, 429 (1998) | (7) Y. Hirokawa, et al.; J. Med. Chem. 46, 702 (2003) | (8) M.A. Osinski, et al.; Pharmacol. Biochem. Behav. 81, 211 (2005)